RxDoctor Payments Data

Robert Candipan, MD

Interventional Cardiology · Mesa, AZNPI 1457375529

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $22,212 of the $32,153 with a category attached, or 69.1%. Medtronic accounts for 75.7% of it on its own, with 39 other manufacturers making up the rest.

$32,153in general payments, 2019–2025

Across 344 payments — averaging $93.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$24K
  • Cardiovascular Systems Inc.$2K
  • Shockwave Medical, Inc$806
  • Impulse Dynamics (USA) Inc.$588
  • Merck$545
  • Novartis$528
  • plus $3K from 34 others
$1,063in research payments, 2019–2025

Across 1 payment — averaging $1063.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$1K

What the payments were for

  • Travel & lodging$22,21269%
  • Food & beverage$9,92731%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,153 in reported general payments places this provider in the 80th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,291,326
Medicare patients
997
Services billed
4,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$136,439
EntrestoSacubitril/Valsartan49$53,452
XareltoRivaroxaban36$40,313
Repatha SureclickEvolocumab32$30,828
BrilintaTicagrelor21$12,548
ClopidogrelClopidogrel Bisulfate329$3,660
Ranolazine ErRanolazine23$2,316
Metoprolol Succinate192$2,241
Atorvastatin Calcium209$2,211
Losartan Potassium139$1,529
Rosuvastatin Calcium104$1,407
Amiodarone Hcl17$1,313
Carvedilol110$1,027
Ezetimibe40$875
SotalolSotalol Hcl19$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$528$53,45249 claims
Johnson & JohnsonXarelto$279$40,31336 claims
AstraZenecaBrilinta$126$12,54821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →